SCHEMBL25673249

SCHEMBL25673249

CCOC(C)n1cc(-c2ncn3nc(NC4CCNCC4)nc3c2OC)cn1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 4/20 0.38
JAK1 P23458 4/20 0.38
TYK2 P29597 4/20 0.38
JAK3 P52333 4/20 0.38
MAPK8 P45983 1/20 0.37
MKNK1 Q9BUB5 2/20 0.35
TYRO3 Q06418 2/20 0.34
LRRK2 Q5S007 1/20 0.33
AXL P30530 1/20 0.32
FLT3 P36888 1/20 0.32
MERTK Q12866 1/20 0.32
CDK2 P24941 2/20 0.32
CDK9 P50750 2/20 0.32
MKNK2 Q9HBH9 1/20 0.32
PSEN1 P49768 1/20 0.31
PSEN2 P49810 1/20 0.31
APH1B Q8WW43 1/20 0.31
NCSTN Q92542 1/20 0.31
APH1A Q96BI3 1/20 0.31
PSENEN Q9NZ42 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31160641 0.93 JAK2 (0.38) JAK2JAK1TYK2JAK3MAPK8
SCHEMBL23209435 0.87 CCNE1 (0.43) JAK2JAK1JAK3CDK2CDK9
SCHEMBL31423960 0.84 JAK2 (0.38) JAK2JAK1TYK2JAK3LRRK2
SCHEMBL31160713 0.81 JAK2 (0.35) JAK2JAK1TYK2JAK3
SCHEMBL23233965 0.81 JAK2 (0.36) JAK2JAK1TYK2JAK3CD274
SCHEMBL31423994 0.80 JAK2 (0.39) JAK2JAK1TYK2JAK3CD274
SCHEMBL23209372 0.80 CCNE1 (0.42) JAK2JAK1JAK3CDK2CDK9
SCHEMBL31160742 0.80 CCNE1 (0.37) JAK2JAK1TYK2JAK3CDK2
SCHEMBL25269598 0.80 MAPK8 (0.39) JAK2JAK3MAPK8MKNK1TYRO3
SCHEMBL31423986 0.79 JAK2 (0.36) JAK2JAK1TYK2JAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230183251-A1 BICYCLIC AMINES AS CDK12 INHIBITORS INCYTE CORPORATION 2023-06-15 US disclosed
US-20230183251-A1 BICYCLIC AMINES AS CDK12 INHIBITORS INCYTE CORPORATION 2023-06-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230183251-A1 BICYCLIC AMINES AS CDK12 INHIBITORS CDK12, CDK1, CDK2 JAK2 379/4885JAK1 672/4885TYK2 296/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.